Skip to content

Blinatumomab effectively replaces conventional chemotherapy cycles for pediatric patients with B-ALL
Iberdomide combination improves MRD–negative complete response rates versus DVd in relapsed or refractory multiple myeloma
Experts offer advice on treating patients with belantamab mafodotin-based combinations in myeloma
Incorporating blinatumomab into frontline therapy for high-risk B-ALL improves MRD, survival outcomes
Saad Usmani, MD, discusses iberdomide approval in relapsed multiple myeloma

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates/Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Acute Myeloid Leukemia

Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Myelodysplastic Syndromes News

FDA accepts BLA for Orca-T in hematological malignancies

by SOHO Insider Editors
October 15, 2025
0 Comments

Leukemia News SOHO 2025 Educational Resources Acute Myeloid Leukemia Meetings / Conferences News

Future Role of CPX-351 and CPX-351-Based Combinations

by SOHO Insider Editors
October 15, 2025
0 Comments

Leukemia Acute Myeloid Leukemia SOHO Insider Podcast

Dr. Eytan Stein joins Dr. Saad Usmani on SOHO Insider podcast

by SOHO Insider Editors
October 9, 2025
0 Comments

Leukemia Acute Myeloid Leukemia

Enasidenib plus venetoclax shows activity in relapsed or refractory IDH2-mutated AML

by Leah Sherwood
October 8, 2025
0 Comments

Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

Radiation from medical imaging increases risk of blood cancers in children

by Leah Sherwood
October 2, 2025
0 Comments

Leukemia Acute Myeloid Leukemia

BLA submitted to FDA for pivekimab sunirine in BPDCN

by Leah Sherwood
October 1, 2025
0 Comments

Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia News

Anthony G. Letai, MD, PhD, sworn in as NCI Director

by Leah Sherwood
September 29, 2025
0 Comments

Leukemia Acute Myeloid Leukemia News

FDA grants Orphan Drug Designation for AK117 (ligufalimab)

by SOHO Insider Editors
September 23, 2025
0 Comments

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Acute Myeloid Leukemia Myelodysplastic Syndromes

Oral decitabine and cedazuridine combo shows promise as post-HSCT option

by Leah Sherwood
August 21, 2025
0 Comments

Acute Myeloid Leukemia Myelodysplastic Syndromes

Treatment post-relapse improves survival outcomes in patients with AML or MDS

by SOHO Insider Editors
August 11, 2025
0 Comments

1
2
3
4
5
6

Top Categories

Cellular Therapy

81

Leukemia

140

Lymphoma

142

Multiple Myeloma

122

Myelodysplastic Syndromes

51

Myeloproliferative Neoplasms

40

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Acute Myeloid Leukemia

FDA accepts BLA for Orca-T in hematological malignancies

Future Role of CPX-351 and CPX-351-Based Combinations

Dr. Eytan Stein joins Dr. Saad Usmani on SOHO Insider podcast

Enasidenib plus venetoclax shows activity in relapsed or refractory IDH2-mutated AML

Radiation from medical imaging increases risk of blood cancers in children

BLA submitted to FDA for pivekimab sunirine in BPDCN

Anthony G. Letai, MD, PhD, sworn in as NCI Director

FDA grants Orphan Drug Designation for AK117 (ligufalimab)

Oral decitabine and cedazuridine combo shows promise as post-HSCT option

Treatment post-relapse improves survival outcomes in patients with AML or MDS

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Blinatumomab effectively replaces conventional chemotherapy cycles for pediatric patients with B-ALL

Iberdomide combination improves MRD–negative complete response rates versus DVd in relapsed or refractory multiple myeloma

Experts offer advice on treating patients with belantamab mafodotin-based combinations in myeloma

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Acute Myeloid Leukemia

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms